Q3 EPS loss of $0.44 was in line with our estimate of $0.44, driven by R&D of $1.18 million that met our forecast and slightly higher G&A of $1.32 million. Management now expects the cash runway to extend into 2027, following the recently announced Q4 financing, which we model in our new 2027 forecast. Final Phase 1b cohort data for PH-762 was positive, with tumor clearance reported in all patients and a favorable safety review at the maximum dose. Clinical momentum is building, and we expect additional catalysts of FDA Phase 1b review news, Phase 2 expansion study design, and potential Investigational New Drug (IND) filings for PH-894, and potential partnerships. We maintain our estimates for the fourth quarter of 2025, 2025, and 2026. We also introduce our full-year 2027 forecast. We continue to assign a High Risk rating, given the early stage of commercialization and continued operating losses.